BRCA2 Protein

"BRCA2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)

Descriptor ID	D024682
MeSH Number(s)	D12.776.313.249 D12.776.624.776.101 D12.776.660.105
Concept/Terms	BRCA2 Protein BRCA2 Protein FANCD1 Protein Fanconi Anemia Complementation Group D1 Protein Fanconi Anemia Group D1 Protein BRCA2 Gene Product Breast Cancer 2 Gene Product Fanconi Anemia Group D1 Complementing Protein Breast Cancer 2 Protein

Below are MeSH descriptors whose meaning is more general than "BRCA2 Protein".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Fanconi Anemia Complementation Group Proteins [D12.776.313]
BRCA2 Protein [D12.776.313.249]
Neoplasm Proteins [D12.776.624]
Tumor Suppressor Proteins [D12.776.624.776]
BRCA2 Protein [D12.776.624.776.101]
Nuclear Proteins [D12.776.660]
BRCA2 Protein [D12.776.660.105]

Below are MeSH descriptors whose meaning is related to "BRCA2 Protein".

Below are MeSH descriptors whose meaning is more specific than "BRCA2 Protein".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "BRCA2 Protein" by people in this website by year, and whether "BRCA2 Protein" was a major or minor topic of these publications.

Bar chart showing 22 publications over 15 distinct years, with a maximum of 5 publications in 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1999	0	1	1
2001	0	2	2
2005	0	1	1
2006	1	0	1
2007	1	0	1
2008	0	1	1
2011	0	1	1
2012	0	2	2
2014	1	0	1
2015	1	0	1
2016	2	0	2
2017	4	1	5
2021	1	0	1
2022	0	1	1
2023	0	1	1

Below are the most recent publications written about "BRCA2 Protein" by people in Profiles.

Kunwor R, Silver DP, Abu-Khalaf M. PARP Inhibitors for the Treatment of BRCA1/2-Mutated Metastatic Breast Cancer: A Systematic Review and Meta-analysis. Hematol Oncol Stem Cell Ther. 2023 Apr 04; 16(3):186-196.

View in: PubMed
Evron E, Ben-David MA, Kaidar-Person O, Corn BW. Nonsurgical Options for Risk Reduction of Contralateral Breast Cancer in BRCA Mutation Carriers With Early-Stage Breast Cancer. J Clin Oncol. 2023 Feb 10; 41(5):964-969.

View in: PubMed
Guzmán-Arocho YD, Rosenberg SM, Garber JE, Vardeh H, Poorvu PD, Ruddy KJ, Kirkner G, Snow C, Tamimi RM, Peppercorn J, Schapira L, Borges VF, Come SE, Brachtel EF, Marotti JD, Warner E, Partridge AH, Collins LC. Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer. Br J Cancer. 2022 02; 126(2):302-309.

View in: PubMed
Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410.

View in: PubMed
Liu J, Kruswick A, Dang H, Tran AD, Kwon SM, Wang XW, Oberdoerffer P. Ubiquitin-specific protease 21 stabilizes BRCA2 to control DNA repair and tumor growth. Nat Commun. 2017 07 26; 8(1):137.

View in: PubMed
Golan T, Raitses-Gurevich M, Kelley RK, Bocobo AG, Borgida A, Shroff RT, Holter S, Gallinger S, Ahn DH, Aderka D, Apurva J, Bekaii-Saab T, Friedman E, Javle M. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study. Oncologist. 2017 07; 22(7):804-810.

View in: PubMed
Chae YK, Davis AA, Jain S, Santa-Maria C, Flaum L, Beaubier N, Platanias LC, Gradishar W, Giles FJ, Cristofanilli M. Concordance of Genomic Alterations by Next-Generation Sequencing in Tumor Tissue versus Circulating Tumor DNA in Breast Cancer. Mol Cancer Ther. 2017 Jul; 16(7):1412-1420.

View in: PubMed
Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR. BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer. Br J Cancer. 2017 Apr 11; 116(8):1021-1026.

View in: PubMed
Sturgeon KM, Dean LT, Heroux M, Kane J, Bauer T, Palmer E, Long J, Lynch S, Jacobs L, Sarwer DB, Leonard MB, Schmitz K. Commercially available lifestyle modification program: randomized controlled trial addressing heart and bone health in BRCA1/2+ breast cancer survivors after risk-reducing salpingo-oophorectomy. J Cancer Surviv. 2017 04; 11(2):246-255.

View in: PubMed
Catts ZA, Baig MK, Milewski B, Keywan C, Guarino M, Petrelli N. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds. Ann Surg Oncol. 2016 May; 23(5):1729-35.

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement